ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Current capacity 1000 tests per day

<< Previous

Bullboard Posts

Next >>

Comment by Thenorth1990on Sep 30, 2021 3:59pm

133 Views

Post# 33947259

RE:RE:Current capacity 1000 tests per day

Nothing new , this accreditation was there from the day when they put it out on requisition form, thanks to rc and then they pulled it out. Can't find anything under pending applications for HC, so really don't know what to expect. But hey they can hide behind forward looking statement disclosure. Next milestone is probably an update on the IND application and we don't have worry about cash from another 18 months

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks